A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia

Inclusion Criteria: * Subjects who were diagnosed with non-dialysis chronic kidney disease (CKD) and who are considered not to require renal replacement therapy during the study period * Mean of the subject's two most recent Hb values before randomization during the Screening Period must be \<10.5 g/dL with an absolute difference ≤1.3 g/dL between the two values * Either transferrin saturation ≥ 5% or serum ferritin ≥ 30 ng/mL * Female subject must either: Be of non-childbearing potential: * post-menopausal prior to pre-screening, or * documented surgically sterile Or, if of childbearing potential, * Agree not to try to become pregnant during the study after informed consent acquisition and for 28 days after the final study drug administration * And have a negative urine pregnancy test at pre-screening * And, if heterosexually active, agree to consistently use two forms of highly effective birth control (at least one of which must be a barrier method) starting at pre-screening and throughout the study period and for 28 days after the final study drug administration. * Female subject must agree not to breastfeed starting at pre-screening and throughout the study period, and for 28 days after the final study drug administration. * Female subject must not donate ova starting at pre-screening and throughout the study period, and for 28 days after the final study drug administration. * Male subject and their female spouse/partners who are of childbearing potential must be using two forms of highly effective birth control (at least one of which must be a barrier method) starting at pre-screening and continue throughout the study period, and for 12 weeks after the final study drug administration * Male subject must not donate sperm starting at pre-screening and throughout the study period, and for 12 weeks after the final study drug administration Exclusion Criteria: * Concurrent retinal neovascular lesion requiring treatment and macular edema requiring treatment * Concurrent autoimmune disease with inflammation that could impact erythropoiesis * History of gastric/intestinal resection considered influential on the absorption of drugs in the gastrointestinal tract (excluding resection of gastric or colon polyps) or concurrent gastroparesis * Uncontrolled hypertension * Concurrent congestive heart failure (NYHA Class III or higher) * History of hospitalization for treatment of stroke, myocardial infarction, or pulmonary embolism within 12 weeks before the pre-screening assessment * Positive for hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus (HCV) antibody at the pre-screening assessment, or positive for human immunodeficiency virus (HIV) in a past test * Concurrent other form of anemia than renal anemia * Having received treatment with ESA, protein anabolic hormone, testosterone enanthate, or mepitiostane within 6 weeks before the pre-screening assessment * Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) or total bilirubin that is greater than the criteria, or previous or concurrent another serious liver disease at pre-screening assessment * Previous or current malignant tumor (no recurrence for at least 5 years is eligible.) * Having undergone red blood transfusion and/or a surgical procedure considered to promote anemia within 4 weeks before the pre-screening assessment * Having undergone a kidney transplantation * History of serious drug allergy including anaphylactic shock * Having a previous history of treatment with ASP1517 * Participation in another clinical study or post-marketing clinical study (including that of a medical device) within 12 weeks before informed consent acquisition